News

Fusion Antibodies Collaborates with Queen’s University on Knowledge Transfer Partnership Programme

Fusion Antibodies, a leading antibody discovery and development company, and Queen’s University Belfast, (173rd ranked University worldwide) have launched a fourth collaboration through a Knowledge Transfer Partnership (KTP). The new programme will allow for the development of an innovative software solution for the design of antibody libraries. The solution will be integrated into the service offering provided by Fusion Antibodies in antibody engineering, to transform capabilities and competitiveness in the antibody discovery space.

Knowledge Transfer Partnerships (KTP) is a UK-wide programme that has been helping businesses in the UK to innovate and grow for over 40 years. KTPs are funded by UKRI through Innovate UK with the support of co-funders, including the Scottish Funding Council, Welsh Government, Invest Northern Ireland, Defra and BEIS. Innovate UK manages the KTP Programme and facilitates its delivery through a range of partners including the Knowledge Transfer Network (KTN), Knowledge Bases and Businesses.

Queen’s University Belfast has partnered with businesses through the KTP initiative for over 25 years, and in May 2019 was the winner of the National Award for ‘Outstanding Contribution from a KTP Support Team’.

Paul Kerr, CEO of Fusion Antibodies commented “We are delighted to partner with Queen’s University through their Knowledge Transfer Partnership programme.  We have worked with Queen’s on multiple KTPs that have provided us with extraordinary talent and resources. Linking with the brightest minds in academia allows us to add another dimension to the knowledge-based service that we offer in the early stages of antibody discovery and development. “

Through the KTP programme, the partnership aims to recruit a suitably qualified software graduate to work in Fusion Antibodies on a collaborative project over an 18-month period.

“I am delighted that Fusion Antibodies are continuing their commitment to the KTP programme and Queen’s University. Their commitment to helping biotech companies deliver treatments for previously unmet medical needs offers graduates an opportunity to learn from both academic and industry experts. KTP sets them on the path to become future industry leaders, bringing to life the strategic plans of an innovative company such as Fusion Antibodies.” Lorraine Marks, Head of KTP and Business Engagement Programmes at Queens University Belfast.

About Fusion Antibodies

Fusion Antibodies delivers new technology and innovation throughout early-stage antibody discovery. As a drug discovery and research partner, our scientists increase the pace to the clinic by guiding clients to develop the best antibodies possible. Through the early stages of drug discovery, we enable biotechnology and pharmaceutical organisations towards their end-goal – the provision of treatments that improve the lives of patients throughout the world.

About Queen’s University, Belfast

Queen’s University Belfast is one of the leading universities in the UK and Ireland, with a distinguished heritage and history. With over 24,000 students, 4,200 staff and an annual turnover of some £300m, Queen’s University Belfast plays a unique leadership role in Northern Ireland. As a member of the Russell Group of UK research-intensive universities, Queen’s University Belfast combines excellence in research and education with a student-centred ethos.